Literature DB >> 17110397

Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.

J Smitz1, A N Andersen, P Devroey, J-C Arce.   

Abstract

BACKGROUND: Highly purified menotrophin (HP-hMG) has been associated with fewer oocytes retrieved and a higher proportion of top-quality embryos compared with recombinant FSH (rFSH).
METHODS: A randomized, assessor-blind, multinational trial in 731 women undergoing IVF after stimulation with HP-hMG (MENOPUR) (n = 363) or rFSH (GONAL-F) (n = 368) following a long GnRH agonist protocol was conducted. Blood was collected before, during and after stimulation. Fluid was collected from follicles > or =17 mm.
RESULTS: Serum androstenedione, total testosterone and free androgen index (FAI) were higher (P < 0.001) with HP-hMG than with rFSH after starting stimulation. At the end of stimulation, serum estradiol was higher (P = 0.031) with HP-hMG, whereas progesterone was higher (P < 0.001) with rFSH, even after adjusting for ovarian response. Serum LH was not different between treatments. Mean mid- and end-follicular hCG levels in the HP-hMG group were 2.5 and 2.9 IU/l, respectively. Follicular fluid levels of FSH, LH, hCG, androstenedione, testosterone, FAI and estradiol and ratios of estradiol:androstenedione, estradiol:total testosterone and estradiol:progesterone were higher (P < 0.001) with HP-hMG, whereas progesterone was higher (P < 0.001) with rFSH.
CONCLUSION: Major differences in serum and follicular fluid endocrine profile exist after stimulation with HP-hMG or rFSH. Exogenous LH activity induces a differential endocrine environment influencing oocyte quantity and quality, which may be of relevance for clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110397     DOI: 10.1093/humrep/del445

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  42 in total

1.  Exposing cultured mouse ovarian follicles under increased gonadotropin tonus to aromatizable androgens influences the steroid balance and reduces oocyte meiotic capacity.

Authors:  Sergio Romero; Johan Smitz
Journal:  Endocrine       Date:  2010-07-20       Impact factor: 3.633

Review 2.  The curious case of premature luteinization.

Authors:  Apostolos Kaponis; Elpiniki Chronopoulou; George Decavalas
Journal:  J Assist Reprod Genet       Date:  2018-07-26       Impact factor: 3.412

3.  Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol.

Authors:  Chan Woo Park; Yu Im Hwang; Hwa Seon Koo; Inn Soo Kang; Kwang Moon Yang; In Ok Song
Journal:  Clin Exp Reprod Med       Date:  2014-12-31

4.  Follicular fluid steroid hormone levels are associated with fertilization outcome after intracytoplasmic sperm injection.

Authors:  Julie D Lamb; A Musa Zamah; Shehua Shen; Charles McCulloch; Marcelle I Cedars; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2009-07-09       Impact factor: 7.329

5.  Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.

Authors:  Daniel A Dumesic; Timothy G Lesnick; Jacques P Stassart; G David Ball; Ashley Wong; David H Abbott
Journal:  Fertil Steril       Date:  2009-07       Impact factor: 7.329

Review 6.  Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis.

Authors:  Philippe Lehert; Joan C Schertz; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2010-09-16       Impact factor: 5.211

Review 7.  Revisiting debates of premature luteinization and its effect on assisted reproductive technology outcome.

Authors:  Reda S Hussein; Ihab Elnashar; Ahmed F Amin; Hisham A Abou-Taleb; Ahmed M Abbas; Ahmed M Abdelmageed; Tarek Farghaly; Yulian Zhao
Journal:  J Assist Reprod Genet       Date:  2019-10-25       Impact factor: 3.412

8.  Follicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: effects of recombinant LH administration.

Authors:  Marzia Barberi; Beatrice Ermini; Maria Beatrice Morelli; Michele Ermini; Sandra Cecconi; Rita Canipari
Journal:  J Assist Reprod Genet       Date:  2012-11-28       Impact factor: 3.412

9.  Study of clinical experience with different approaches to controlled ovarian hyperstimulation: a focus on safety and efficacy.

Authors:  Svetoslav Stoev; Ilko Getov; Tanya Timeva; Emilia K Naseva; Hristina Lebanova; Boyka Petkova
Journal:  Eur J Hosp Pharm       Date:  2019-05-04

10.  A Randomized Controlled Trial on the Efficacy and Safety of Low-Dose hCG in a Short Protocol with GnRH Agonist and Ovarian Stimulation with Recombinant FSH (rFSH) During the Follicular Phase in Infertile Women Undergoing ART.

Authors:  Charalampos Siristatidis; Sofoklis Stavros; Konstantinos Dafopoulos; Theodoros Sergentanis; Ekaterini Domali; Peter Drakakis; Dimitrios Loutradis
Journal:  Reprod Sci       Date:  2021-07-12       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.